Fevipiprant
A slowly dissociating CRTh2 antagonist with Kd of 1.14 nM; shows a half-life of 14.4 minutes, >7-fold slower than AZD-1981; inhibits PGD2-stimulated human eosinophil shape change, importantly, retains its potency in the whole-blood shape-change assay relative to the isolated shape change assay; also is a potent inhibitor of PGD2-induced cytokine release in human Th2 cells.Asthma Phase 3 Clinical (In Vitro) :Fevipiprant (0-10 μM) inhibits the gene expression of IL-4, IL-3, IL-5, IL-8, CSF1, CSF2 in n in human Th2 cells induced by activated mast cell supernatants. (In Vivo) :Fevipiprant (10 mg/kg; in the drinking water) reduces CaCl2-induced AAA (abdominal aortic aneurysm) formation in mouse.
Product Specifications
CAS Number
872365-14-5
Product Name Alternative
NVP-QAW039 | QAW-039
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 32 mg/mL
Smiles
O=C (O) CC1=C (C) N (CC2=CC=C (S (=O) (C) =O) C=C2C (F) (F) F) C3=NC=CC=C31
Molecular Formula
C19H17F3N2O4S
Molecular Weight
426.4095
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1H-Pyrrolo[2,3-b]pyridine-3-acetic acid, 2-methyl-1-[[4- (methylsulfonyl) -2- (trifluoromethyl) phenyl]methyl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
